CJC-1295 + Ipamorelin
CJC-1295 + Ipamorelin
CJC-1295 + Ipamorelin 10mg laboratory research vial. CJC-1295 + Ipamorelin is a two-component blend. Compare sizes and lot-specific COAs. Not for human or animal consumption.

Compound information
- Compound identity
- CJC-1295 + Ipamorelin
Reference values describe the named chemical form. Consult the lot-specific report for the material supplied.
Vial sizes and availability
- 10mg · $84.15 USD · In stock · estimated dispatch up to 2 weeks · Select 10mg
- 20mg · $76.50 USD · In stock · estimated dispatch 2-3 business days · Select 20mg
Material identity and evidence limits
CJC-1295 + Ipamorelin is a two-component blend. Confirm the CJC form and each component amount on the actual batch record.
CJC-1295 + Ipamorelin: match each component to its evidence
A blend name does not identify whether its CJC component contains DAC, nor does a total mass disclose the amount of each component. This page does not assign an unverified CJC form or blend ratio. Match those details to the actual batch record before comparing a publication or certificate.
The selected 2006 CJC-1295 studies concern a long-acting, albumin-binding analog and GH/IGF-I measurements in healthy adults. They are not trials of this mixture. A finding for one component does not establish that combining two compounds improves muscle, sleep or recovery.
Raun and colleagues’ 1998 ipamorelin study used rat pituitary cells, rats and pigs; its selectivity findings are not general human safety evidence. Human research also exists: Beck and colleagues’ 2014 placebo-controlled bowel-surgery trial enrolled 117 patients, with 114 in the safety and modified intention-to-treat analyses. Its key solid-meal-tolerance endpoint was not statistically significant (p = 0.15). Neither paper validates this blend or catalog lot.
- Teichman et al., 2006: CJC-1295 alone in healthy adults
- Ionescu and Frohman, 2006: albumin-binding CJC-1295
- Raun et al., 1998: preclinical ipamorelin pharmacology
- Beck et al., 2014: randomized postoperative ipamorelin trial
Compare identity and documentation: CJC-1295 with DAC · CJC-1295 no DAC · Ipamorelin alone
Certificates of analysis
- KMD Analytical — RSK-20260916-E65T-01 · Lot CJCIPA1010-RESET/KAR-09142026 · Reported purity: CJC-1295: 99.92% · Ipamorelin: 99.21% · CJC-1295 + Ipamorelin documentation
Certificates of analysis · COA Library · Research purchaser requirements
Match the full compound identity, size and lot to the original report. Availability and purchaser eligibility must be confirmed before fulfillment.
Browse all compounds · Compound reference index · How to read a COA